Drug therapies for chronic hepatitis C infection: a cost-effectiveness analysis.

ABSTRACT:

Background

Before 2011, pegylated interferon plus ribavirin was the standard therapy for chronic hepatitis C. Interferon-free direct-acting antiviral agents were then approved. Although these treatments appear to be more effective, they are substantially more expensive. In anticipation of the need for information regarding the comparative cost-effectiveness of new regimens in a recent therapeutic review, we conducted the analysis to inform listing decision in Canada.

Methods

A state-transition model was developed in the form of a cost-utility analysis. Regimens included in the analysis were comprehensive. The cohort under consideration had a mean age of 50 years. The cohort was defined by treatment status and cirrhosis status. Inputs for the model were derived from published

SUBMITTER: Wong WW 

PROVIDER: S-EPMC5378540 | biostudies-literature | 2017 Jan-Mar

REPOSITORIES: biostudies-literature